Population Impact and Effectiveness of Monovalent Rotavirus Vaccination in Urban Malawian Children 3 Years after Vaccine Introduction: Ecological and Case-Control Analyses

Clinical Infectious Diseases

Volumn 62, Issue , 2016, Pages S213-S219

  Bar Zeev, Naor ^a,b   Jere, Khuzwayo C ^a,b   Bennett, Aisleen ^a,b   Pollock, Louisa ^a,b   Tate, Jacqueline E ^c   Nakagomi, Osamu ^d   Iturriza Gomara, Miren ^b   Costello, Anthony ^e   Mwansambo, Charles ^f   Parashar, Umesh D ^c   Heyderman, Robert S ^a,e,g   French, Neil ^a,b   Cunliffe, Nigel A ^b   Beard, James ^h   Crampin, Amelia C ^h   King, Carina ^h   Lewycka, Sonia ^h   Mvula, Hazzie ^h   Phiri, Tambosi ^h   Verani, Jennifer R ^h   Whitney, Cynthia G ^h   more..

^a UNIVERSITY OF MALAWI   (Malawi)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^d NAGASAKI UNIVERSITY   (Japan)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f MINISTRY OF HEALTH   (Malawi)

^g LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^h NONE

Author keywords

case control; developing countries; population impact; rotavirus vaccine; vaccine effectiveness

Indexed keywords

ROTAVIRUS VACCINE; LIVE VACCINE; RIX4414 VACCINE; VACCINE;

AGE DISTRIBUTION; ARTICLE; CHILD; CHILD HOSPITALIZATION; CLINICAL EFFECTIVENESS; DIARRHEA; ENVIRONMENTAL EXPOSURE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INCIDENCE; INFANT; MALAWIAN; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; ROTAVIRUS INFECTION; STUNTING; URBAN POPULATION; VACCINATION; CASE CONTROL STUDY; COMPLICATION; EPIDEMIOLOGICAL MONITORING; FECES; FEMALE; GASTROENTERITIS; GENETICS; GROWTH DISORDERS; HIV INFECTIONS; HOSPITALIZATION; IMMUNOLOGY; ISOLATION AND PURIFICATION; MALAWI; PRESCHOOL CHILD; ROTAVIRUS; ROTAVIRUS INFECTIONS; STATISTICS AND NUMERICAL DATA; TRENDS; URBAN HEALTH; VIROLOGY; VULNERABLE POPULATION;

CASE-CONTROL STUDIES; CHILD, PRESCHOOL; DIARRHEA; EPIDEMIOLOGICAL MONITORING; FECES; FEMALE; GASTROENTERITIS; GENOTYPE; GROWTH DISORDERS; HIV INFECTIONS; HOSPITALIZATION; HUMANS; INFANT; MALAWI; PREVALENCE; ROTAVIRUS; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; URBAN HEALTH; VACCINATION; VACCINE POTENCY; VACCINES, ATTENUATED; VULNERABLE POPULATIONS;

EID: 84965102794     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ1183     Document Type: Article

References (40)

1. Madhi SA, Cunliffe NA, Steele D, et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med 2010; 362:289-98.
2. World Health Organization, Strategic Advisory Group of Experts. Meeting of the immunization Strategic Advisory Group of Experts, April 2009-conclusions and recommendations. Wkly Epidemiol Rec 2009; 84:213-36.
3. Program for AppropriateTechnologies in Health (PATH). Rotavirus vaccine access and delivery. 2014. Available at: http://sites.path.org/rotavirusvaccine/countryintroduction-maps-and-spreadsheet/. Accessed 3 January 2016.
4. Groome MJ, Page N, Cortese MM, et al. Effectiveness of monovalent human rotavirus vaccine against admission to hospital for acute rotavirus diarrhoea in South African children: A case-control study. Lancet Infect Dis 2014; 14:1096-104.
5. Bar-Zeev N, Kapanda L, Tate JE, et al. Effectiveness of a monovalent rotavirus vaccine in infants in Malawi after programmatic roll-out: an observational and casecontrol study. Lancet Infect Dis 2015; 15:422-8.
6. Bar-Zeev N, Tate JE, Pecenka C, et al. Cost-effectiveness of monovalent rotavirus vaccination of infants in Malawi: A postintroduction analysis using individual patient-level costing data. Clin Infect Dis 2016; 62(suppl 2):S220-8.
7. Correia JB, Patel MM, Nakagomi O, et al. Effectiveness of monovalent rotavirus vaccine (Rotarix) against severe diarrhea caused by serotypically unrelated G2P [4] strains in Brazil. J Infect Dis 2010; 201:363-9.
8. Patel M, Pedreira C, De Oliveira LH, et al. Association between pentavalent rotavirus vaccine and severe rotavirus diarrhea among children in Nicaragua. JAMA 2009; 301:2243-51.
9. Cunliffe NA,Witte D, Ngwira BM, et al. Efficacy of human rotavirus vaccine against severe gastroenteritis in Malawian children in the first two years of life: A randomized, double-blind, placebo controlled trial. Vaccine 2012; 30(suppl 1):A36-43.
10. Keusch GT, Rosenberg IH, Denno DM, et al. Implications of acquired environmental enteric dysfunction for growth and stunting in infants and children living in low-and middle-income countries. Food Nutr Bull 2013; 34:357-64.
11. Afran L, Garcia Knight M, Nduati E, Urban BC, Heyderman RS, Rowland-Jones SL. HIV-exposed uninfected children: A growing population with a vulnerable immune system? Clin Exp Immunol 2014; 176:11-22.
12. Chihana ML, Price A, Floyd S, et al. Maternal HIV status associated with underfive mortality in rural northern Malawi: A prospective cohort study. J Acquir Immune Defic Syndr 2015; 68:81-90.
13. Steele AD, Madhi SA, Louw CE, et al. Safety, reactogenicity, and immunogenicity of human rotavirus vaccine RIX4414 in human immunodeficiency virus-positive infants in South Africa. Pediatr Infect Dis J 2011; 30:125-30.
14. Steele AD, Cunliffe N, Tumbo J, Madhi SA, De Vos B, Bouckenooghe A. A review of rotavirus infection in and vaccination of human immunodeficiency virusinfected children. J Infect Dis 2009; 200(suppl):S57-62.
15. Cunliffe NA, Gondwe JS, Broadhead RL, et al. Rotavirus G and P types in children with acute diarrhea in Blantyre, Malawi, from 1997 to 1998: predominance of novel P[6]G8 strains. J Med Virol 1999; 57:308-12.
16. Cunliffe NA, Ngwira BM, Dove W, et al. Epidemiology of rotavirus infection in children in Blantyre, Malawi, 1997-2007. J Infect Dis 2010; 202(suppl):S168-74.
17. Steele AD, Neuzil KM, Cunliffe NA, et al. Human rotavirus vaccine Rotarixprovides protection against diverse circulating rotavirus strains in African infants: A randomized controlled trial. BMC Infect Dis 2012; 12:213-20.
18. Velasquez DE, Parashar UD, Jiang B. Strain diversity plays no major role in the varying efficacy of rotavirus vaccines: an overview. Infect Genet Evol 2014; 28:561-71.
19. Bar-Zeev N, Kapanda L, King C, et al. Methods and challenges in measuring the impact of national pneumococcal and rotavirus vaccine introduction on morbidity and mortality in Malawi. Vaccine 2015; 33:2637-45.
20. Turner A, Ngwira B, Witte D, Mwapasa M, Dove W, Cunliffe N. Surveillance of rotavirus gastro-enteritis in children in Blantyre, Malawi. Paediatr Int Child Health 2013; 33:42-5.
21. Ruuska T, Vesikari T. Rotavirus disease in Finnish children: use of numerical scores for clinical severity of diarrhoeal episodes. Scand J Infect Dis 1990; 22:259-67.
22. World Health Organization, Expanded Programme on Immunization. Manual of rotavirus detection and characterization methods. Geneva, Switzerland: WHO, 2009.
23. Gautam R, Esona MD, Mijatovic-Rustempasic S, Ian Tam K, Gentsch JR, Bowen MD. Real-time RT-PCR assays to differentiate wild-type group A rotavirus strains from Rotarix((R)) and RotaTeq((R)) vaccine strains in stool samples. Hum Vaccin Immunother 2014; 10:767-77.
24. Malawi Ministry of Health. Malawi integrated guidelines for providing HIV services. Lilongwe: Malawi Ministry of Health, 2011.
25. Royston P. PTREND: Stata module for trend analysis for proportions. 2002. Available at: http://EconPapers.repec.org/RePEc:boc:bocode:s426101. Accessed 25 July 2014.
26. Brown LD, Cai TT, DasGupta A. Interval estimation for a binomial proportion. Stat Sci 2001; 16:101-33.
27. National Statistics Office. Malawi census of population and housing 2008. Zomba, Malawi: National Statistics Office, 2009.
28. Hanquet G, Valenciano M, Simondon F, Moren A. Vaccine effects and impact of vaccination programmes in post-licensure studies. Vaccine 2013; 31:5634-42.
29. Mantel N. Chi-square tests with one degree of freedom, extensions of the Mantel-Haenszel procedure. J Am Stat Assoc 1963; 58:690-700.
30. Patel MM, Tate J, Cortese M, et al. The impact of indirect benefits of vaccination on postlicensure vaccine effectiveness estimates: A scenario analysis. Vaccine 2010; 28:7987-92.
31. Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006; 354:11-22.
32. Gurgel RQ, Cuevas LE, Vieira SC, et al. Predominance of rotavirus P[4]G2 in a vaccinated population, Brazil. Emerg Infect Dis 2007; 13:1571-3.
33. Zeller M, Rahman M, Heylen E, et al. Rotavirus incidence and genotype distribution before and after national rotavirus vaccine introduction in Belgium. Vaccine 2010; 28:7507-13.
34. Donato CM, Zhang ZA, Donker NC, Kirkwood CD. Characterization of G2P[4] rotavirus strains associated with increased detection in Australian states using the RotaTeq(R) vaccine during the 2010-2011 surveillance period. Infect Gen Evol 2014; 28:398-412.
35. Fujii Y, Nakagomi T, Nishimura N, et al. Spread and predominance in Japan of novel G1P[8] double-reassortant rotavirus strains possessing a DS-1-like genotype constellation typical of G2P[4] strains. Infect Gen Evol 2014; 28:426-33.
36. Kosek M, Guerrant RL, Kang G, et al. Assessment of environmental enteropathy in the MAL-ED cohort study: theoretical and analytic framework. Clin Infect Dis 2014; 59(suppl 4):S239-47.
37. Wittes J, Wallenstein S. The power of the Mantel-Haenszel test. J Am Stat Assoc 1987; 82:1104-9.
38. Comstock GW. Evaluating vaccination effectiveness and vaccine efficacy by means of case-control studies. Epidemiol Rev 1994; 16:77-89.
39. Orenstein WA, Bernier RH, Dondero TJ, et al. Field evaluation of vaccine efficacy. Bull World Health Organ 1985; 63:1055-68.
40. Orenstein WA, Bernier RH, Hinman AR. Assessing vaccine efficacy in the field. Further observations. Epidemiol Rev 1988; 10:212-41.